Bourgeon Capital Management’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-550
| Closed | -$34.4K | – | 158 |
|
|
2023
Q4 | $34.4K | Buy |
550
+500
| +1,000% | +$31.3K | 0.01% | 172 |
|
|
2023
Q3 | $2.27K | Hold |
50
| – | – | ﹤0.01% | 287 |
|
|
2023
Q2 | $2.81K | Sell |
50
-2,000
| -98% | -$112K | ﹤0.01% | 287 |
|
|
2023
Q1 | $92.7K | Buy |
2,050
+1,550
| +310% | +$70.1K | 0.02% | 120 |
|
|
2022
Q4 | $20.3K | Hold |
500
| – | – | 0.01% | 199 |
|
|
2022
Q3 | $33K | Hold |
500
| – | – | 0.01% | 153 |
|
|
2022
Q2 | $30K | Sell |
500
-1,300
| -72% | -$78K | 0.01% | 159 |
|
|
2022
Q1 | $113K | Buy |
1,800
+750
| +71% | +$47.1K | 0.03% | 118 |
|
|
2021
Q4 | $80K | Buy |
1,050
+500
| +91% | +$38.1K | 0.02% | 131 |
|
|
2021
Q3 | $62K | Buy |
+550
| New | +$62K | 0.01% | 153 |
|
|
2021
Q1 | – | Sell |
-100
| Closed | -$15K | – | 282 |
|
|
2020
Q4 | $15K | Buy |
+100
| New | +$15K | ﹤0.01% | 198 |
|